London-based activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk (NVO) as the Ozempic-maker hunts for a new CEO following a share price slump, people with knowledge of the matter told Financial Times’ Oliver Barnes and Hannah Kuchler. The hedge fund wants to influence the appointment of Novo Nordisk’s new Chief Executive, the report stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Roche’s Chugai Seeks Next Milestone after Finding Success with Eli Lilly’s Obesity Drug
- Novo Nordisk Stock (NVO) Shakes off Links Between Weight Jabs and Vision Loss
- Unusually active option classes on open June 6th
- Study finds GLP-1s may have link to eye disease, STAT reports
- Eli Lilly Stock (LLY) Grows Despite U.K. Warnings to Pregnant Women Over Weight Loss Jabs
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue